Skip header and navigation
COVID-19 Rapid Evidence Reviews
  Refine Search

22 records – page 1 of 3.

How effective are COVID-19 vaccines?

https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc295
Document Type
Table
Review Code
INF031801v019 RR Table
Question Submitted
March 18, 2021
Date Completed
December 26, 2021
Status
5. Updated review
Research Team
Infectious Disease
for protection against all infections for both non-Delta and Delta variants 2-Nov-21 Immunity pfizer Goldberg Y
More detail
Document Type
Table
Review Code
INF031801v019 RR Table
Question Submitted
March 18, 2021
Date Completed
December 26, 2021
Status
5. Updated review
Research Team
Infectious Disease
Category
Epidemiology
Infection Prevention and Control
Subject
Vaccines
Immunity
Infection Prevention and Control
Clinical Presentation
Population
All
Clinical Setting
Community
ICU
Medicine Unit
Primary care
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Jagwani, M; Lee, S; Shumilak, G; Reeder, B; Groot, G; Hernandez, L; Howell-Spooner, B; Miller, L. How effective are COVID-19 vaccines? 2021 Dec 26; Document no.: INF031801v019 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. (CEST Table)
Similar Reviews
EOC011901 RR
EOC031001 RR
Review History
INF031801v17 RR: November 23, 2021
INF031801v16 RR: November 12, 2021
INF031801v15 RR: October 28, 2021
INF031801v014 RR: October 16, 2021
INF031801v013 RR: September 24, 2021
INF031801v012 RR: September 10, 2021
INF031801v010 RR: August 25, 2021
INF031801v9 RR: August 23, 2021
INF031801v8 RR: August 9, 2021
INF031801v7 RR: July 20, 2021
INF031801v6 RR: July 2, 2021
INF031801v5 RR: June 22, 2021
INF031801v4 RR: June 3, 2021
INF031801v3 RR: May 24, 2021
INF031801v2 RR: May 14, 2021
INF031801 RR: March 31, 2021
Related Documents
Documents

INF031801v019 RR Table

Download File
Less detail

How effective are COVID-19 vaccines? [Evergreen]

https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc413
Document Type
Rapid Review
Review Code
INF031801v019 RR
Question Submitted
March 18, 2021
Date Completed
December 26, 2021
Status
5. Updated review
Research Team
Infectious Disease
More detail
Document Type
Rapid Review
Review Code
INF031801v019 RR
Question Submitted
March 18, 2021
Date Completed
December 26, 2021
Status
5. Updated review
Research Team
Infectious Disease
Updated Key Findings
December 14, 2021
Ontario Immunization Advisory Committee recommended that if an 11 and 12-year-old child is inadvertently given a second dose of the Pfizer-BioNTech vaccine that is not authorized for their age, the dose should be considered valid and the series complete.
National Advisory Committee on Immunization (NACI) recommends that a booster dose of an authorized mRNA COVID-19 vaccine should be offered to vulnerable population and > 50 years old, =6 months after completion of a primary COVID-19 vaccine series.
Australian Technical Advisory Group on Immunization (ATAGI) recommends COVID-19 booster vaccination with either Pfizer (Comirnaty) or Moderna (Spikevax), which are considered equally acceptable, for anyone aged 18 and older who completed their primary course of COVID-19 vaccination 5 or more months ago.
On December 8th, 2021 in a press release by Pfizer-BioNTech said that preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 vaccine neutralize the Omicron variant while two doses show significantly reduced neutralization titers. Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses.
Key Findings
December 3, 2021
The Therapeutic Goods Administration (TGA) has granted provisional approval to Moderna for the use of its vaccine in children (two 10µg doses) and as booster shot for adults (one 30µg dose) in preparation for the recent emergence of the Omicron variant. This is in addition to Pfizer, which was also recently approved.
The National Advisory Committee on Immunization (NACI) recommends that a complete series with the Pfizer-BioNTech COVID-19 vaccine (10 mcg) may be offered to children 5-11 years of age who do not have contraindications to the vaccine, with a dosing interval of at least 8 weeks between the first and second dose.
NNACI also recommends that children aged 5-11 years with a history of previous SARS-CoV-2 infection should be considered no longer infectious and symptoms of an acute illness should be completely resolved prior to vaccination.
Health Canada has authorized Moderna's COVID-19 vaccine (also known as Spikevax) to be used as a booster shot, using a half-dose of the vaccine.
Category
Epidemiology
Infection Prevention and Control
Subject
Vaccines
Immunity
Infection Prevention and Control
Clinical Presentation
Population
All
Clinical Setting
Community
ICU
Medicine Unit
Primary care
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Jagwani, M; Lee, S; Shumilak, G; Reeder, B; Groot, G; Hernandez, L; Howell-Spooner, B; Miller, L. How effective are COVID-19 vaccines? 2021 Dec 26. Document no.: INF031801v019 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 93 p. (CEST rapid review report)
Review History
INF031801v17 RR: November 23, 2021
INF031801v16 RR: November 12, 2021
INF031801v15 RR: October 28, 2021
INF031801v014 RR: October 16, 2021
INF031801v013 RR: September 24, 2021
INF031801v012 RR: September 10, 2021
INF031801v010 RR: August 25, 2021
INF031801v9 RR: August 23, 2021
INF031801v8 RR: August 9, 2021
INF031801v7 RR: July 20, 2021
INF031801v6 RR: July 2, 2021
INF031801v5 RR: June 22, 2021
INF031801v4 RR: June 3, 2021
INF031801v3 RR: May 24, 2021
INF031801v2 RR: May 14, 2021
INF031801 RR: March 31, 2021
Related Documents
Documents
thumbnail

INF031801v019 RR

Read PDF Download PDF
Less detail

How effective are COVID-19 vaccines? [Evergreen]

https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc425
Document Type
Evidence Search Report
Review Code
INF031801v020 ESR
Question Submitted
March 18, 2021
Date Completed
January 14, 2022
Status
5. Updated review
Research Team
Infectious Disease
; preventing ventilation; preventing “long COVID” (long term symptoms), duration of immunity (natural
More detail
Document Type
Evidence Search Report
Review Code
INF031801v020 ESR
Question Submitted
March 18, 2021
Date Completed
January 14, 2022
Status
5. Updated review
Research Team
Infectious Disease
Category
Epidemiology
Infection Prevention and Control
Subject
Vaccines
Infection Prevention and Control
Clinical Presentation
Immunity
Population
All
Clinical Setting
Community
ICU
Medicine Unit
Primary care
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Miller, L., Howell-Spooner, B. How effective are COVID-19 vaccines? 2022 Jan 14, Document no.: INF031801v020 ESR . In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 9 p. (CEST evidence search report).
Similar Reviews
EOC220304
Review History
INF031801v17 RR: November 23, 2021
INF031801v16 RR: November 12, 2021
INF031801v15 RR: October 28, 2021
INF031801v014 RR: October 16, 2021
INF031801v013 RR: September 24, 2021
INF031801v012 RR: September 10, 2021
INF031801v010 RR: August 25, 2021
INF031801v9 RR: August 23, 2021
INF031801v8 RR: August 9, 2021
INF031801v7 RR: July 20, 2021
INF031801v6 RR: July 2, 2021
INF031801v5 RR: June 22, 2021
INF031801v4 RR: June 3, 2021
INF031801v3 RR: May 24, 2021
INF031801v2 RR: May 14, 2021
INF031801 RR: March 31, 2021
Related Documents
Documents
thumbnail

INF031801v020 ESR

Read PDF Download PDF
Less detail

Is the IgM or IgG immune response protective?

https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc38
Document Type
Evidence Search Report
Review Code
LAB040803-01 ESR
Question Submitted
April 8, 2020
Date Completed
April 8, 2020
Status
3. Completed
Research Team
Laboratory
1 SUMMARIES, GUIDELINES & OTHER RESOURCES Excerpt from UptoDate Immunity — Antibodies
More detail
Document Type
Evidence Search Report
Review Code
LAB040803-01 ESR
Question Submitted
April 8, 2020
Date Completed
April 8, 2020
Status
3. Completed
Research Team
Laboratory
Category
Clinical Presentation
Subject
Testing
Serology
Immunity
Natural History
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Duncan, V. Is the IgM or IgG immune response protective? 2020 Apr 8; Document no.: LAB040803-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 13 p. (CEST evidence search report)
Related Documents
Documents
thumbnail

LAB040803-01 ESR

Read PDF Download PDF
Less detail

Is the IgM or IgG immune response protective?

https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc48
Document Type
Rapid Review
Review Code
LAB040803 RR
Question Submitted
April 8, 2020
Date Completed
April 11, 2020
Status
3. Completed
Research Team
Laboratory
, which is suggestive of protective humoral immunity in COVID-19 patients with mild to moderate symptoms
More detail
Document Type
Rapid Review
Review Code
LAB040803 RR
Question Submitted
April 8, 2020
Date Completed
April 11, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
Low grade evidence shows IgG and IgM antibody response correlates with neutralizingantibody titerand viral clearance, which is suggestive of protective humoral immunity inCOVID-19 patients with mild to moderate symptoms.
There is no available evidence with which to estimate the durability of this protective response. However, if the immune response to SARS-CoV-2 resembles that toward SARS-CoV, this protective humoral immunity may persist for several years.
Higher IgG antibody titersand a robustresponse were noted in severe to criticallyill patients and were associated with lower viral clearance and a worse clinical prognosis.
Low grade evidence suggests that convalescent plasma treatment may improve the clinical status of critically ill COVID-19 patients(one case series with only five patients enrolled).
Category
Clinical Presentation
Subject
Testing
Serology
Immunity
Natural History
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Wang, H; Reeder, B; Duncan, V; Is the IgM or IgG immune response protective? 2020 Apr 11; Document no.: LAB040803 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 6 p. (CEST rapid review report)
Related Documents
Documents
thumbnail

LAB040803 RR

Read PDF Download PDF
Less detail

Is there evidence that children under 18 should receive the booster to increase their immunity?

https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc436
Document Type
Table
Review Code
EOC220102 RR Table
Question Submitted
January 10, 2022
Date Completed
February 4, 2022
Status
6. Cancelled
Research Team
EOC
: Is there evidence that children under 18 should receive the booster to increase their immunity? Review Code
More detail
Document Type
Table
Review Code
EOC220102 RR Table
Question Submitted
January 10, 2022
Date Completed
February 4, 2022
Status
6. Cancelled
Research Team
EOC
Notes
EOC220102
Category
Epidemiology
Infection Prevention and Control
Subject
Immunity
Infection Prevention and Control
Pediatrics
Public Health
Vaccination
Priority Level
Level 2 One week (7 days)
Cite As
Badea, A; Reeder, B; Groot, G; Dalidowicz, M; Fox, L. Is there evidence that children under 18 should receive an mRNA vaccine booster/3rd dose? 2022 Feb 04, Document no.: EOC220102 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. (CEST table).
Related Documents
Documents

EOC220102 RR Table

Download File
Less detail

Is there evidence that children under 18 should receive the booster to increase their immunity?

https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc438
Document Type
Rapid Review
Review Code
EOC220102 RR
Question Submitted
January 10, 2022
Date Completed
February 4, 2022
Status
6. Cancelled
Research Team
EOC
to increase their immunity? Review Code: EOC220102 RR Review Date: February 4, 2022 Version: 1
More detail
Document Type
Rapid Review
Review Code
EOC220102 RR
Question Submitted
January 10, 2022
Date Completed
February 4, 2022
Status
6. Cancelled
Research Team
EOC
Key Findings
The CDC has released a recommendation that all adolescents 12-17 be offered booster vaccines using only the Pfizer COVID-19 vaccine, at least 5 months following the primary series
The CDC guidelines follow the review of unpublished Israeli data of 12-15 year olds vaccinated 5-6 months prior showing an equivalent infection rate to unvaccinated, and that those who receive boosters are at about 1/3 of the risk
Health Canada has not yet approved booster doses for general use in 12-17 year olds, however NACI has recommended that boosters, at least 6 months following the primary series, should be considered for the following groups within that age group o Those with an underlying medical condition at high risk of severe illness due to COVID-19 (including those who are immunocompromised and received a 3-dose primary series) o Those who are residents in congregate settings (e.g. shelters, group homes, quarters for migrant workers, correctional facilities) o Those who belong to racialized and/or marginalized communities disproportionately affected by COVID-19
Notes
Updated Review cancelled due to insufficient evidence
Category
Epidemiology
Infection Prevention and Control
Subject
Immunity
Infection Prevention and Control
Pediatrics
Public Health
Vaccination
Priority Level
Level 2 One week (7 days)
Cite As
Badea, A; Reeder, B; Groot, G; Dalidowicz, M; Fox, L. Is there evidence that children under 18 should receive the booster to increase their immunity? 2022 Feb 04, Document no.: EOC220102 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 8 p. (CEST rapid review report).
Related Documents
Documents
thumbnail

EOC220102 RR

Read PDF Download PDF
Less detail

Is there evidence that children under 18 should receive the booster to increase their immunity?

https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc466
Document Type
Evidence Search Report
Review Code
EOC220102v002 ESR
Question Submitted
January 10, 2022
Date Completed
April 6, 2022
Status
6. Cancelled
Research Team
EOC
that children under 18 should receive the booster to increase their immunity? Context: Evidence
More detail
Document Type
Evidence Search Report
Review Code
EOC220102v002 ESR
Question Submitted
January 10, 2022
Date Completed
April 6, 2022
Status
6. Cancelled
Research Team
EOC
Notes
Updated review not currently planned.
Category
Epidemiology
Infection Prevention and Control
Subject
Immunity
Infection Prevention and Control
Pediatrics
Public Health
Vaccination
Priority Level
Level 2 One week (7 days)
Cite As
Dalidowicz, M; Fox, L. Is there evidence that children under 18 should receive the booster to increase their immunity? 2022 Apr 06, Document no.: EOC220102v002 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 11 p. (CEST rapid review report).
Related Documents
Documents
thumbnail

EOC220102v002 ESR

Read PDF Download PDF
Less detail

What is known about hybrid immunity to COVID-19?

https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc480
Document Type
Evidence Search Report
Review Code
INF220501 ESR
Question Submitted
May 16, 2022
Date Completed
May 18, 2022
Status
3. Completed
Research Team
Infectious Disease
immunity to COVID-19? Context: Review Code: INF220501 ESR Complete Date: May 18, 2022 Cite
More detail
Document Type
Evidence Search Report
Review Code
INF220501 ESR
Question Submitted
May 16, 2022
Date Completed
May 18, 2022
Status
3. Completed
Research Team
Infectious Disease
Category
Clinical Presentation
Diagnostics
Subject
Immunity
Infection Prevention and Control
Vaccination
Population
All
Clinical Setting
Community
Public Health
Priority Level
Level 4 Three weeks (21 days)
Cite As
Fox, L; Miller, L. What is known about hybrid immunity to COVID-19? 2022 May 18, Document no.: INF220501 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 41 p. (CEST evidence search report).
Related Documents
Documents
thumbnail

INF220501 ESR

Read PDF Download PDF
Less detail

What is known about hybrid immunity to COVID-19?

https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc496
Document Type
Table
Review Code
INF220501 RR Table
Question Submitted
May 16, 2022
Date Completed
June 6, 2022
Status
3. Completed
Research Team
Infectious Disease
: What is known about hybrid immunity to COVID-19? Review Code: INF220501 RR Table Version: 1 Review
More detail
Document Type
Table
Review Code
INF220501 RR Table
Question Submitted
May 16, 2022
Date Completed
June 6, 2022
Status
3. Completed
Research Team
Infectious Disease
Category
Clinical Presentation
Diagnostics
Subject
Immunity
Infection Prevention and Control
Vaccination
Population
All
Clinical Setting
Community
Public Health
Priority Level
Level 4 Three weeks (21 days)
Cite As
Groot, G; Reeder, B; Muhajarine, N; Lee, S; Badea, A; Fox, L; Miller, L. What is known about hybrid immunity to COVID-19? 2022 Jun 06, Document no.: INF220501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. (CEST table).
Related Documents
Documents

INF220501 RR Table

Download File
Less detail

22 records – page 1 of 3.